Search clinical trials for: Placebo Paclitaxel

Total 57268 results

Merck Sharp & Dohme LLC

Terminated

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

Stage IIIB or IV Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Corcept Therapeutics
Gynecologic Oncology Group

Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, Korea, Republic of, Poland, Spain, United Kingdom
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group Limited

Completed

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Esophageal Squamous Cell Carcinoma

China
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Tianjin Medical University Cancer Institute and...

Unknown

Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer

Metastatic Breast Cancer

China
B. Braun Medical International Trading Company...

Completed

A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD)

Coronary Instent Restenosis

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Georgetown University

Recruiting

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer (ProGem)

Metastatic Pancreatic Cancer

United States
Novartis Pharmaceuticals

Completed

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Neoplasms, Breast

United States
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Shanghai Chest Hospital
Sun Yat-sen University; Fudan University; Fujian Cancer Hospital; Hunan Cancer... and other collaborators

Unknown

Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer

Esophageal Neoplasms

China
Jinling Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy

China
Fondazione Michelangelo

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (ETNA)

Breast Cancer

Spain, Australia, Singapore, Italy, Germany, Russian Federation
Celgene Corporation

Completed

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (SNAPIST-III)

Coronary Restenosis
Sun Yat-sen University

Active, not recruiting

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Recurrent Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute
First Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaborators

Unknown

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Breast Cancer
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, Australia, Brazil, Czech Republic, Russian Federation, Singapore
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Hao Long

Active, not recruiting

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer (NeoTAP01)

Non Small Cell Lung Cancer

China
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College

Unknown

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

Non-small Cell Lung Cancer
Hao Long

Recruiting

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Chemotherapy | Safety | Biomarker | Tislelizumab

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer

Early-stage Breast Cancer | Breast Cancer Invasive | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

China
Fifth Affiliated Hospital, Sun Yat-Sen University
Dongguan People's Hospital

Recruiting

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Treatment

China
Zhejiang Cancer Hospital
Shanghai Junshi Bioscience Co., Ltd.

Suspended

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinoma

China
Assistance Publique - Hôpitaux de Paris
Bard Peripheral Vascular, Inc.

Completed

Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula (ABISS)

Angioplasty | Stenosis of Arteriovenous Fistula

France
Daiichi Sankyo, Inc.

Terminated

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

Chile, Argentina
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
NSABP Foundation Inc
Celgene Corporation

Completed

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Breast Neoplasms

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Breast Cancer | Neoadjuvant Chemotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Tang-Du Hospital

Recruiting

Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

Thymoma and Thymic Carcinoma

China
All India Institute of Medical Sciences, New Delhi

Unknown

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Metastatic Carcinoma to the Uterine Cervix | Recurrent Carcinoma Cervix | Cervix Carcinoma Recurrent

India
West China Hospital

Recruiting

Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC (neoCHANCE-2)

Head and Neck Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...
Sun Yat-sen University; Peking University International Hospital; Zhejiang University

Not yet recruiting

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

HER2-positive Breast Cancer | Brain Metastases

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
Sun Yat-sen University

Unknown

Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Nasopharyngeal Cancer | Non Small Cell Lung Cancer | Liver Metastasis

China
Health Science Center of Xi'an Jiaotong University

Completed

Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus

Squamous Carcinoma of Esophagus | Esophagus Disorders

China
Lucas Vieira dos Santos
Fundação de Amparo à Pesquisa do Estado de São Paulo; University of Campinas...

Terminated

Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer (METTAX)

Head and Neck Neoplasms | Squamous Cell Carcinoma

Brazil
Spanish Cooperative Group for the Treatment of...

Completed

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (SEQUENCE)

Metastatic Pancreatic Adenocarcinoma

Spain
Fudan University

Unknown

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Breast Cancer

China
University of Michigan Rogel Cancer Center
Celgene Corporation

Terminated

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Bladder Cancer | Urothelial Cancer

United States

Search clinical trials for: Placebo Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations